Thirty-Third Board Meeting

Professor Christian Otu Onyebuchi Chukwu from the West and Central Africa constituency is designated as Rapporteur for the Thirty-Third Board Meeting.

<p>The agenda for the Thirty-Third Board Meeting (GF/B33/01 - Revision 2) is approved.</p>

The Board appoints Norbert Hauser as Chair of the Board and Aida Kurtovic as Vice -Chair of the Board to each serve a term starting from the adjournment of the Thirty-Third Board Meeting on 1 April 2015 and until the adjournment of the first in person Board Meeting in 2017.

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's Annual Financial Report 2014, which includes the 2014 Consolidated Financial Statements that have been audited by Ernst &amp; Young SA, as set forth in Annex 1 to GF/B33/03 - Revision 1.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2014 Statutory Financial Statements, which have been audited by Ernst &amp; Young SA, as set forth in Annex 2 to GF/B33/03 - Revision 1. </p>

<p>The Board appoints Ernst &amp; Young SA as the Global Fund's external auditor for the 2015 fiscal year.</p>

<ol> <li>The Board: <ol type="a"> <li>Notes additional analysis was required to finalize the performance targets for the updated 2014 - 2016 Global Fund Corporate Key Performance Indicator Framework (the "KPI Framework") that was approved in November 2014 (GF/B32/DP10); and</li> <li>Acknowledges the Secretariat's presentation of 2014 performance assessments and updates, as well as updated performance targets, for the KPI Framework, as set forth in GF/B33/04B.</li> </ol> </li> <li>Accordingly, the Board approves the updated performance targets for Key Performance Indicators 6, 12 and 16, as presented in GF/B33/04B.</li> </ol>

<ol> <li>The Board acknowledges its approval of an interim measure for the financing of Hepatitis C virus treatment until the approval of a broader policy on co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria (GF/B32/DP07).</li> <li>Based on the recommendations of the Strategy, Investment and Impact Committee, the Board approves the framework for financing co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria, as set forth in GF/B33/11.</li> <li>Accordingly, the Board notes this decision point supersedes GF/B32/DP07.</li> </ol>

<ol> <li>The Board approves a reporting arrangement for the Ethics Officer as follows: <ol type="a"> <li>The Ethics Officer will report on its activities directly to the Board through the Committee responsible for ethics matters (the "Committee").</li> <li>The Ethics Officer will provide regular advice and support: <ol type="i"> <li>To the Executive Director on ethical matters pertaining to the Secretariat's activities, including issues related to grant recipients, CCMs, third-party providers (e.g., LFAs and suppliers) and staff. Based on the Ethics Officer's advice, the Executive Director will determine and implement appropriate remedial actions.</li> <li>To the Committee on all other ethical matters not included in paragraph 1(b)(i) above. Based on the Ethics Officer's advice, the Committee will determine appropriate remedial actions.</li> </ol> </li> <li>The Ethics Officer will be located within the Office of the Inspector General for administrative purposes only. </li> </ol> </li> </ol>

<ol> <li>The Board acknowledges the Audit and Ethics Committee's second stage policy proposals as set forth in document GF/B33/15 - Revision.</li> <li>Accordingly, the Board: <ol type="a"> <li>Approves the Code of Ethical Conduct for Governance Officials contained in Annex A to GF/B33/15 - Revision 2; and</li> <li>Notes that the Code of Ethical Conduct for Governance Officials will be reviewed following appointment of the Ethics Officer. This review will be conducted by the Board Leadership in collaboration with the Committee responsible for ethics matters (the "Committee"). The findings of the review will be presented to the Board for discussion and potential revisions to the Code of Ethical Conduct as applicable.</li> </ol> </li> <li>In addition, the Board: <ol type="a"> <li>Notes the Board's decision to approve the reporting arrangements for the Ethics Officer described in GF/B33/DP09;</li> <li>Endorses, in principle, the Terms of Reference of the Ethics Officer contained in Annex B to GF/B33/15 - Revision 2; and</li> <li>Requests that the Terms of Reference of the Ethics Officer be further developed by the Board Leadership in collaboration with the Committee, with the support of the Office of the Inspector General, through a comprehensive consultation process and submitted to the Board through the Committee for approval by June 2015.</li> </ol> </li> <li>Following approval by the Board of the Terms of Reference of the Ethics Officer in June 2015, the recruitment process will be launched.</li> </ol>

<ol><li>The Board expresses its deep appreciation to Dr Nafsiah Mboi for her leadership as Chair of the Board. She has served the Global Fund with a high degree of personal commitment and passion. During her tenure, Ibu Naf has presided over significant deliberations and decisions that will continue to shape the future of the Global Fund. </li><li>The Board also expresses sincere gratitude to Ambassador Mireille Guigaz for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and distinction. During her tenure, Mireille has been an active driver of discussions and initiatives that will have a lasting impact on the Global Fund. </li><li>Their stewardship of the Board through the launch of a new funding model, an ethics and integrity initiative, and the approval of a governance plan for impact have pointed the Global Fund towards continued success and efficiency in achieving its mission. </li><li>The Board wishes Ibu Naf and Mireille every success in their future endeavors and bestows upon them the honorary titles of Chair Emeritus and Vice-Chair Emeritus of the Board, respectively. </li></ol>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER01;</li> <li>Approves the reinvestment of newly identified existing funds for the Ukraine TB/HIV program and its constituent grants and its resultant total program budget, as listed in Table 2 of Annex 1 to GF/B33/ER01;</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</p> <p>Annex: Armenia TB - Ministry of Health of the Republic of Armenia (ARM-T-MOH), Bhutan - TB - Ministry of Health of Bhutan (BTN-T-MOH), Costa Rica - HIV - Humanist Institute for Cooperation (HIVOS) (CRI-H-HIVOS), Eritrea - Malaria - Ministry of Health of Eritrea (ERI-M-MOH), Iraq - TB - UNDP (IRQ-T-UNDP), UKR-C-AUA, UKR-C-AUN, UKR-C-UCDC.</p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 3 of Annex 1 to GF/B33/ER01.</li> </ol> <p>This decision does not have material budgetary implications for the 2014 Operating Expenses Budget.</p> <p>Annex: Cameroon (CMR-011-G10-H), Cameroon (CMR-011-G11-H), Indonesia (IND-M-MOH), Sudan (SUD-011-G15-H), Thailand (THA-H-DDC).</p>

<p>The Board approves the appointment of Ms. Sandra Roelofs as a voting member of the Strategy, Investment and Impact Committee (the “SIIC)”) for a term that will expire on 9 March 2016, or until the appointment of her successor.</p>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER03 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Bhutan (BTN-M-MOH), Ethiopia (ETH-S-FMOH, ETH-M-FMOH), Gambia (GMB-H-NAS, GMB-H-ActionAid), Guinea (GIN-M-CRS), Lao (People Democratic Republic) (LAO-T-GFMOH), Mozambique (MOZ-M-MOH, MOZ-M-WV, MOZ-H-MOH, MOZ-T-MOH, MOZ-C-FDC), Papua New Guinea (PNG-H-OSHF), Philippines (PHL-H-SC), Sao Tome &amp; Principe (STP-T-UNDP), Senegal (SEN-H-ANCS, SEN-H-CNLS), Somalia (SOM-H-UNICEF, SOM-M-UNICEF), South Sudan (SSD-T-UNDP), Tanzania (TZA-H-MOF, TZA-T-MOF), Uganda (UGA-S-MoFPED, UGA-S-TASO, UGA-C-TASO, UGA-H-MoFPED, UGA-T-MoFPED), Viet Nam (VNM-H-VAAC, VNM-H-VUSTA, VNM-T-NTP) and Yemen (YEM-M-NMCP).</p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER03.</li> </ol> <p>Annex: Malawi (MLW-H-NAC), Multi Country Americas REDCA+ HIV Grant (MAR-H-SICSA).</p>

<p>The Board approves the appointment of Mr. Michael Ruffner as the non-voting, neutral Vice-Chair of the Finance and Operational Performance Committee (the "FOPC") for the remainder of his predecessor's term.</p>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER05 – Revision 1 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Bhutan (BTN-H-MOH), Bulgaria (BGR-T-MOH), Burkina Faso (BFA-T-PADS, BFA-H-SPCNLS, BFA-C-IPC), Cambodia (KHM-M-UNOPS), Cape Verde (CPV-M-CCSSIDA), Côte d'Ivoire (CIV-M-PNLP), Eritrea (ERI-T-MOH, ERI-H-MOH), Ethiopia (ETH-H-HAPCO, ETH-T-FMOH), Fiji (FJI-T-MHMS), Ghana (GHA-H-ADRA, GHA-H-PPAG, GHA-H-MOH, GHA-H-GAC, GHA-T-MOH), Mauritius (MUS-H-NAS, MUS-H-PILS), Multicountry Western Pacific (QMJ-C-UNDP, QMJ-M-UNDP), Nicaragua (NIC-H-INSS), Niger (NER-H-CISLS), Pakistan (PAK-T-NTP, PAK-T-MC), Russian Federation (RUS-H-OHI), Rwanda (RWA-T-MOH, RWA-H-MOH), Solomon Islands (SLB-M-MHMS, SLB-T-MHMS), Sudan (SDN-H-UNDP), Swaziland (SWZ-T-NERCHA) and Tanzania (TZA-C-STC).</p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER05 – Revision 1.</li> </ol> <p>Annex: Guatemala (GUA-610-G04-T), Haiti (HTI-102-G09-H), India (IDA-T-CTD), Lao (PDR) (LAO-708-G09-M), Nepal (NEP-H-SCF, NEP-M-SCF), Syria (SYR-607-G01-T), Zanzibar (ZAN-T-MOHSW).</p>

<p>#</p>

<p>The Board approves the Report of the Thirty-Third Board Meeting, as set forth in GF/B33/24.</p>

The Board decides to convene the Thirty-Fourth Board Meeting in Geneva, Switzerland as an exception to article B.6.1 of the Operating Procedures of the Board and Committees.

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Afghanistan (AFG-M-UNDP), Botswana (BWA-M-BMOH), Comoros (COM-T-ASCOBEF), Congo (Democratic Republic) (COD-H-CORDAID, COD-H-SANRU, COD-H-MOH, COD-T-CARITAS, COD-H-MCOD-T-MOH), Somalia (SOM-T-WV) and Swaziland (SWZ-H-CANGO, SWZ-H-NERCHA).</p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER07.</li> </ol> <p>Annex: Abidjan-Lagos Corridor Organization (MAW-607-G01-H), Djibouti (DJB-613-G05-H), Guinea-Bissau (GNB-M-UNDP), Kosovo (KOS-711-G04-H), Nigeria (NGA-T-IHVN), Pakistan (PKS-M-DOMC PKS-T-NTP).</p>

<ul> <li>Based on the recommendation of the Board Leadership, the Board: <ol type="a"> <li>Approves the Terms of Reference of the Ethics Officer, as set forth in Annex 1 to document GF/B33/ER08; and</li> <li>Notes that the Terms of Reference of the Ethics Officer supersede the Board’s earlier decisions regarding the reporting arrangement for the Ethics Officer (GF/B33/DP09)</li> </ol> </li> <li>Accordingly, the Board instructs the Secretariat to launch the recruitment process for the Ethics Officer, who will be jointly selected by the Audit and Ethics Committee (AEC) and the Executive Director, and appointed by the Board on a no-objection basis for a three-year term that may be renewed no more than once.</li> <li>The Board requests the AEC and Finance and Operational Performance Committee to determine the future budgetary implications of this function as part of the standard Operating Expenses budget approval process, with particular consideration given to methods for maximizing value for money.</li> </ul>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B33/ER09 (“Table 1”);</li> <li>Approves the reinvestment of newly identified existing funds for the Burkina Faso TB/HIV grant (BFA-H-SPCNLS) and its resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER09;</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Belize (BLZ-C-UNDP), Burkina Faso (BFA-S-PADS, BFA-M-PADS), Cambodia (KHM-H-NCHADS, KHM-S-PRMOH), Center for Health and Policy Studies (QMZ-T-PAS), Elimination 8 - SADC (QPA-M-E8S), Guinea (GIN-H-CNLS, GIN-H-PSI), India (IDA-M-NVBDCP, IDA-M-CARITAS, IDA-H-NACO, IDA-H-IHAA, IDA-H-PLAN, IDA-H-SAATHII, IDA-T-CTD, IDA-T-IUATLD, IDA-T-WV), Kenya AIDS NGOs Consortium Regional (QPB-H-KANCO), Kenya (KEN-M-TNT, KEN-M-AMREF, KEN-H-KRCS, KEN-H-TNT, KEN-T-AMREF, KEN-T-TNT), Korea (Democratic People’s Republic) (PRK-T-UNICEF), Lao (People’s Democratic Republic) (LAO-M-GFMOH), South Sudan (SSD-H-UNDP), Sri Lanka (LKA-T-MOH), Sudan (SDN-S-FMOH), Suriname (SUR-C-MOH), Tajikistan (TJK-H-UNDP), Togo (TGO-H-PMT, TGO-T-PMT), Zanzibar (QNB-M-MOH).</p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B33/ER09.</li> </ol> <p>Annex: Liberia (LBR-T-MOH), Madagascar (MDG-809-G11-H, MDG-809-G12-H), Syria (SYR-011-G02-H).</p>

<ol> <li>Based on the recommendations of the Strategy, Investment and Impact Committee, as set forth in GF/B33/ER10, the Board decides the Global Fund’s strategy should cover a period that aligns the start of each strategy cycle to the start of a replenishment and allocation period.</li> <li>Accordingly, the Board decides the next strategy should cover the six-year period that begins on 1 January 2017 and ends on 31 December 2022, with a mid-point review of progress and implementation alongside replenishment.</li> </ol>

<ol> <li>Based on the recommendation of the Transitional Governance Committee, the Board approves the Governance Performance Assessment Framework, as set forth in Annex 1 to GF/B33/ER11 (the “Framework”).</li> <li>The Board agrees with the approach for partially implementing the Framework in 2015, as described in GF/B33/ER11, and acknowledges that full implementation of the Framework will start in 2016.</li> </ol>

<p>The Board approves the appointment of Eiji Hinoshita as a voting member of the Finance and Operational Performance Committee for a term that will expire on 1 May 2016, or until the appointment of his successor. </p>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B33/ER14 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex:</p> <p>Azerbaijan (AZE-T-MOH), Bangladesh (BGD-H-NASP, BGD-H-SC, BGD-H-ICDDRB), Cape Verde (CPV-C-CCSSIDA), Comoros (COM-M-PNLP), Haiti (HTI-C-PSI), Lao (People's Democratic Republic) (LAO-H-GFMOH), Panama (PAN-C-UNDP), Sri Lanka (LKA-M-MOH), Zanzibar (QNB-C-MOH).<br /><br />Regional grants: Abidjan-Lagos Corridor Organization (OCAL) (QPF-H-ALCO), African Network for the Care of Children Affected by HIV/AIDS (ANECCA) (QPA-H-ANECCA), ECSA-HC Uganda Supranational National Reference Laboratory (QPA-T-ECSA), Humanist Institute for Cooperation with Developing Countries, Southern Africa (HIVOS) (QPA-H-HIVOS), Removal of Legal Barriers (RLB) (QPA-H-UNDP).</p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B33/ER14.</li> </ol> <p>Annex:</p> <p>Angola (AGO-M-MOH), Sri Lanka (SRL-607-G07-T, SRL-809-G10-M)</p>

<p>The Board:</p> <ol> <li>Approves waiver of the Board condition imposed in the Congo HIV grant (COG-911-G06-H) restricting the “use of funds to finance activities other than (i) the procurement of Health Products and Pharmaceuticals and (ii) other activities deemed essential in the framework of the program,” and</li> <li>Approves disbursement of grant funds to the principal recipient the Secretariat Executif Permanent/Comité National de Lutte contre le SIDA (SEP /CNLS) to conduct activities essential to the implementation of the HIV program.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV of GF/B33/ER15 ("Table 1");</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex:</p> <p>Dominican Republic (DOM-H-CONAVIH, DOM-H-IDCP0, Lao (People's Democratic Republic) (LAO-S-GFMOH), Malawi (MWI-M-MOH, MWI-M-WVM, MWI-C-MOH)<br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /></p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B33/ER15.</li> </ol> <p>Annex: Kyrgyzstan (KGZ-H-UNDP)</p>

<p>The Board approves the appointment of Dr Suriya Wongkongkathep as a voting member of the Strategy, Investment and Impact Committee for the remainder of his predecessor's two-year term, or until the appointment of his successor.</p>

<ol><li>Based on the recommendations of the Strategy, Investment and Impact Committee (the "SIIC"), as set forth in GF/B33/ER17, the Board decides the next strategy should cover the six-year period that begins on 1 January 2017 and ends on 31 December 2022 (the "2017 - 2022 Strategy"), with a mid-point review of progress and implementation. </li><li>The Board notes the importance of coherence between the strategy, allocation and replenishment, as well as the need to provide advanced articulation of the Global Fund's strategy and objectives to guide implementation planning, facilitate advocacy efforts and support mobilization of resources.</li><li>Accordingly, the Board directs the SIIC, or its successor committee, to develop a timeline for developing and finalizing the strategy that will commence immediately after the 2017 - 2022 Strategy as part of the mid-point review of the 2017 - 2022 Strategy. </li></ol><p><br/></p>

The Board:<br/>1. Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B33/ER18 (collectively, "Table 1");<br/>2. Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Approves the additional funding for the Zimbabwe HIV Program and its resultant total program budget, as listed in Table 1c of Section IV to GF/B33/ER18;<br/>4. Approves the reinvestment of within-allocation efficiencies for the Bangladesh malaria and Cote d'Ivoire malaria grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER18;<br/>5. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.<br/>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.

<p>The Board:<br/><br/>1. Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B33/ER18.</p><p><b>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</b> <br/></p>

1. Acknowledges the current political context and challenging implementation environment in Iraq, Palestine, Syria and Yemen due to ongoing conflicts; and<br/><br/>2. Accordingly, approves the following policy exceptions for processing HIV and TB funding applications from these countries to access relevant 2014-2016 funding allocations:<br/><br/>• Waiver of the CCM eligibility requirements;<br/>• Waiver of the counterpart financing requirement; and<br/>• Waiver of the "willingness-to-pay" requirement<br/><br/><b>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</b>

<p>The Board approves the appointment of Ambassador Lennarth Hjelmaker as a voting member of the Strategy, Investment and Impact Committee for the remainder of his predecessor's two-year term, or until the appointment of his successor. </p>